Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

NCX-4016 fails to meet primary endpoint in phase II study in PAOD patients

Nov. 15, 2005

Series B financing to advance Portola's cardiovascular portfolio

Nov. 10, 2005

European orphan drug designation for alfimeprase for acute PAO

Nov. 10, 2005

Emisphere receives FDA guidance on oral heparin phase III trial

Nov. 9, 2005

Novel antithrombotic agents revealed in patent literature

Nov. 8, 2005

GTC Biotherapeutics and LEO Pharma enter agreement for ATryn

Nov. 7, 2005

Recent Aventis patent claims novel therapeutic agents for thrombotic disorders

Nov. 3, 2005

Pivotal phase III study for ZymoGenetics' rhThrombin

Oct. 31, 2005

Novel anticoagulant agents thrombotic disorders revealed

Oct. 25, 2005

Recombinant protein with exemplary thrombolytic and antithrombotic properties

Oct. 25, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...
AACR D3: ONM-421 shows antigen-independent tumor control
BioWorld Science
At the American Association for Cancer Research’s inaugural Drug Discovery and Development conference (AACR D3), Onconano Medicine Inc. presented preclinical data...